FDA Approved Nanobiotix for First Immuno-Oncology Trial

FDA Approved Nanobiotix for First Immuno-Oncology Trial

Nanobiotix, a nanomedicine announced the approval of U.S. Food and Drug Administration (FDA) on December 26, 2017, for Investigational New Drug (IND) Application.

NBTXR3 is a first in class nanoparticle designed for direct injection into cancerous tumors, which is activated by stereotactic ablative radiotherapy (SABR) and administered into the body with combination of anti-PD1 antibody (nivolumab or pembrolizumab). “Advancing our demonstration of NBTXR3’s potential to turn checkpoint inhibitor non-responders into responders could be game-changing and the approach could address the unmet medical needs of a significant number of patients. Based on existing pre-clinical and clinical data, NBTXR3 could become a backbone in immuno-oncology,” said Laurent Levy, CEO of Nanobiotix.

The study is expected to be conducted in two consecutive phases, which includes dose escalation, followed by a dose expansion phase. 36 to 72 patients are expected to be enrolled in Phase I and 40 patients in Phase II for the study. NBTXR3-1100 includes three cohorts of patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) or with metastatic non-small cell lung cancer (NSCLC). While NBTXR3 and Radiotherapy doses will be escalated and the anti-PD1 antibody dose will remain constant. The dose expansion phase will be selected based on the preliminary risk-benefit ratio assessment observed in Phase I portion of the trial.

Primary and secondary endpoints are expected to evaluate efficacy and safety, while exploratory endpoints characterize the treatment-induced genomic alterations. According to the Immunotherapy Drugs Market report published by Coherent Market Insights, Immuno-oncology therapy enhance, suppress or inducing an immune response. They are useful for treatment for some types of cancer. Immuno-oncology agents can boost immune system response by priming it for active attack against tumor cells. While the response to checkpoint inhibitors is infiltrated by T-cells and characterized by an inflammatory profile, which has long-lasting clinical benefits in cancer patients.

You may be interested

Business

Tricks Used by Insurance Companies to Deny Legit Claims

media - December 10, 2018

Health insurance companies strategize in making more and more money by paying out as little as possible. Many times, they deny legitimate claims which are covered under…

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection
Business
Business

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection

Mohit Joshi - December 10, 2018

Researchers from King's College London revealed that use of sunscreen offers less than half the sun protection as users apply more thinly than manufacturers recommend. In a…

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026
Healthcare
Healthcare

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026

Albert R - December 10, 2018

Tamoxifen Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a valuable source of perceptive information…

Most from this category